Study of GalaFLEX LITE™ Scaffold in Treatment of Capsular Contracture After Breast Implant Augmentation
NCT ID: NCT05945329
Last Updated: 2026-02-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
250 participants
INTERVENTIONAL
2024-12-12
2027-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Force Modulating Tissue Bridges for Closure of Vertical Scars in Breast Reduction
NCT05028816
The SeriScaffold® Use in Reconstruction Post Market Study for Tissue Support and Repair in Breast Reconstruction Surgery in Europe
NCT01389232
Cosmetic Fat Transplantation Using Expanded ASC Enriched Fat Grafts
NCT03258164
The SERI® Surgical Scaffold Use in Reconstruction Post Market Study for Tissue Support and Repair in Breast Reconstruction Surgery
NCT01256502
Poly-4-Hydroxybutyrate Scaffold in Rhytidectomy
NCT07132892
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
GalaFlex Light Scaffold
Surgery performed with GalaFlex Lite Scaffold.
GalaFLEX LITE™ Scaffold
Bioabsorbable surgical mesh manufactured from poly-4-hydroxybutyrate (P4HB) and knitted into a surgical scaffold used to reinforce soft tissue
Standard Surgery
Surgery performed using standard surgical procedures with no scaffold.
Standard surgery
Surgery performed without the use of a scaffold
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GalaFLEX LITE™ Scaffold
Bioabsorbable surgical mesh manufactured from poly-4-hydroxybutyrate (P4HB) and knitted into a surgical scaffold used to reinforce soft tissue
Standard surgery
Surgery performed without the use of a scaffold
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Breast augmentation subject with capsular contracture (Baker grade III or IV);
3. Desired a new implant with no more than a 25% increase in implant size (not to exceed a volume increase greater than 150cc compared to the existing implant);
4. Planned revision approach via inframammary fold (IMF) incision;
5. Willing and able to comply with the study procedures including the 2-year follow-up visit;
6. Lives within 3 hours driving distance from the investigator site; and,
7. Provision of signed and dated informed consent form.
Exclusion Criteria
2. Existing and/or replacement implant size \> 800 cc
3. Had ≥2 capsular contracture revisions on the breast(s) intended for treatment
4. Has an extra-capsular rupture (breast implant silicone gel or saline has leaked outside of the capsule) in breast(s) intended for treatment
5. Has prior use of a matrix (synthetic or biologic) in the breast(s) intended for treatment.
6. Abnormal findings on diagnostic imaging within 1-year of study enrollment (mammogram for patients ≥35 years old; MRI for patients \<35 years old or breast ultrasound if MRI is contraindicated)
7. Has symptoms consistent with Breast Implant Illness (BII)Systemic Symptoms Associated with Breast Implants (SSBI)
8. Infection present in the breast (day of surgery exclusions are noted in Section 5.3)
9. Current or recent breast feeding (within 3-months or enrollment) or history of mastitis within the 6-months prior to enrollment
10. Prior or current diagnosis of breast cancer
11. Has a mass that was palpated and has not been determined benign via acceptable imaging (MRI) or biopsy results
12. Has undergone prior chest radiation treatment
13. Has received chemotherapy within the last 12 months
14. Current or recent (within 1-year of enrollment) alcohol/substance abuse
15. Current or recent (within 4-weeks of enrollment) nicotine user (includes cigarettes, vaping, patches, gum, etc.)
16. History of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) or Breast Implant Associated Squamous Cell Carcinoma (BIA-SCC)
17. Planned use of another type of matrix (such as ADM) in addition to GalaFLEX LITE™
18. Current or planned use of medical (e.g. Singulair), physical (e.g. massage), or device-assisted (e.g. mechanical/thermal ultrasound) tools to manage the breast capsule(s)
19. Any medical condition that, in the opinion of the investigator, may be associated with unduly high risk of intra- or post-operative complications (e.g., insulin-dependent diabetes, autoimmune disease, connective tissue disorder, chronic lung or severe cardiovascular disease)
20. Concurrent or planned (within the 2-year follow-up time period) elective cosmetic breast operation to the treated breast (e.g., autologous fat transfer, mastopexy, or implant size changes)
21. Currently enrolled or has plans to enroll in another clinical study that would interfere with this study, unless it is a retrospective or observational study
22. Is pregnant or plans to become pregnant during the study period
23. Known allergy to tetracycline hydrochloride and kanamycin sulfate
24. Any condition that, in the Investigator's opinion, would preclude the use of the study device, interfere with the evaluation of the device or breast related outcomes
25. Subject will not remain under the care of the investigator for all plastic surgery procedures while enrolled in the study
26. Actively using immunosuppressants such as oral steroids or biological therapies (inhalers or topical steroids are permitted)
27. Confirmed diagnosis of the following rheumatic diseases or syndromes: systemic lupus erythematosus, Sjorgren's syndrome, scleroderma, polymyositis, or any connective tissue disorder, rheumatoid arthritis, crystalline arthritis, infectious arthritis, spondyloarthropathies, any other inflammatory arthritis, fibromyalgia, or chronic fatigue syndrome
28. Has, in the investigator's opinion, a mental illness or disability that would preclude their participation in the study
29. Subject has an implant that was never commercially available in the United States (had their breast augmentation in another country)
30. Has been implanted with any silicone implant other than breast implants
31. Is taking any drugs that would interfere with blood clotting or might result in elevated risk of significant postoperative complications
32. Works for Sponsor or any of their subsidiaries, the study surgeon, or is helping to conduct the study or are directly related to anyone that works for BD or any of their subsidiaries or the study surgeons. -
22 Years
66 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
C. R. Bard
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Practice Plastic Surgery
Beverly Hills, California, United States
Donald S Mowlds, MD A Professional Corporation
Newport Beach, California, United States
Newport Plastic and Reconstructive Surgery Associates
Newport Beach, California, United States
Tim Sayed MD
San Diego, California, United States
Sanctuary Plastic Surgery
Boca Raton, Florida, United States
Careaga Plastic Surgery
Miami, Florida, United States
Billington Plastic Surgery
St. Petersburg, Florida, United States
VIVIFY Plastic Surgery
Tampa, Florida, United States
The Graivier Center
Alpharetta, Georgia, United States
Meridian Plastic Surgery Center
Indianapolis, Indiana, United States
Reno Tahoe Plastic Surgery
Reno, Nevada, United States
Plastic Surgery Institute of New York
New York, New York, United States
H/K/B Surgery
Huntersville, North Carolina, United States
Essential Medical Research
Tulsa, Oklahoma, United States
Pittsburgh Center for Plastic Surgery
Pittsburgh, Pennsylvania, United States
The Plastic Surgery Center of Nashville With HKB
Nashville, Tennessee, United States
Southwest Plastic Surgery
El Paso, Texas, United States
Aesthetic Center for Plastic Surgery
Houston, Texas, United States
The Plastics Clinic
Draper, Utah, United States
Allen Gabriel MD
Vancouver, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DVL-BR-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.